(PPHM, OWW, DSCO) CRWENewswire Stocks In Action

- 0 0
942   12 tahun lalu
karmastock | 0 Pelanggan
942   12 tahun lalu
Peregrine Pharmaceuticals Inc - PPHM - reported preliminary results related with its Bavituximab from a randomized Phase II trial showing a 50% improvement in overall tumor response rates in non-small cell lung cancer patients

KOMENTAR

0